Why is Marksans Pharma falling/rising?

As of 14-Aug, Marksans Pharma Ltd is experiencing a decline in its stock price, currently at Rs 178.30, which reflects a decrease of Rs 8.5 or 4.55%. The stock has underperformed its sector by 4.67% today, reaching an intraday low of Rs 177. The stock's performance over the past week shows a significant drop of 17.26%, and it has also declined by 31.66% over the past month. Despite a high management efficiency indicated by a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, the company has faced challenges with poor long-term growth, as evidenced by a negative annual operating profit growth rate of -0.29% over the last five years. Furthermore, the company reported disappointing quarterly results, with a 38.7% fall in profit after tax compared to the previous four-quarter average, contributing to the stock's downward trend. In the broader market context, while the BSE Sensex has remained relatively stable with a negligible change of -0.03% over the past week, Marksans Pharma's steep decline highlights its struggles compared to the benchmark. The stock has underperformed the market significantly over the past year, with a return of -16.74% against the BSE500's -0.57%. This stark contrast indicates that investor sentiment towards Marksans Pharma is weak, compounded by its expensive valuation reflected in a price-to-book ratio of 3.3, despite a modest profit increase of 4.9% over the same period. The combination of negative financial results and underperformance relative to the market has led to a lack of confidence among investors, further driving the stock price down.